“We are delighted to have gained Uwe Röhrhoff, a proven industry expert, as interim CEO,” said Dr. Axel Herberg, Chairman of the Supervisory Board of Gerresheimer AG. “As former CEO of Gerresheimer, he is extremely knowledgeable about the company and has a very clear understanding of the business and its challenges.”
Dietmar Siemssen steps down as CEO after seven years
Röhrhoff succeeds Dietmar Siemssen, who, by mutual agreement with the Supervisory Board, will step down as CEO on October 31, after seven years in office. He is thus paving the way for a personnel change at the top of the MDAX company.
“We would like to thank Dietmar Siemssen for his commitment and contribution to the strategic development of Gerresheimer,” said Dr. Axel Herberg. “Under his leadership, the company has transformed itself from a volume supplier to a provider of high-value systems and solutions for the pharma and biotech industries.”
Newly formed Management Board
The appointment of Uwe Röhrhoff as interim CEO completes the personnel changes to Gerresheimer's Management Board for the time being. In September 2025, Wolf Lehmann replaced Dr. Bernd Metzner as CFO. On November 1, 2025, Uwe Röhrhoff will succeed Dietmar Siemssen as CEO and Achim Schalk will succeed Dr. Lukas Burkhard as a member of the Management Board.
About Gerresheimer
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.4bn in 2024 and currently employs around 13,600 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
Contact Gerresheimer AG
